Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09NTC
|
|||
| Former ID |
DNCL003453
|
|||
| Drug Name |
CC-486
|
|||
| Synonyms |
AG-14361; AG14361; 328543-09-5; UNII-48N0U0K50I; AG 14361; CHEMBL65892; 48N0U0K50I; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one, 2-[4-[(dimethylamino)methyl]phenyl]-5,6-dihydro-; AG-014361; 1-(4-((dimethylamino)methyl)phenyl)-8,9-dihydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one; Imidazo(4,5,1-jk)(1,4)benzodiazepin-7(4H)-one, 2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydro-; 2-[4-[(Dimethylamino)methyl]phenyl]-5,6-dihydroimidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one; SMR000486393; MLS006011157; MLS001065917; Nucleoside analogue
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 3 | [1] | |
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 3 | [2] | ||
| Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3; ICD-9: 200] | Phase 1 | [1] | ||
| Company |
Celgene
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H20N4O
|
|||
| Canonical SMILES |
CN(C)CC1=CC=C(C=C1)C2=NC3=CC=CC4=C3N2CCNC4=O
|
|||
| InChI |
1S/C19H20N4O/c1-22(2)12-13-6-8-14(9-7-13)18-21-16-5-3-4-15-17(16)23(18)11-10-20-19(15)24/h3-9H,10-12H2,1-2H3,(H,20,24)
|
|||
| InChIKey |
SEKJSSBJKFLZIT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 328543-09-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14801398, 24138480, 44938160, 49645682, 75980483, 99431558, 99460875, 103261452, 104015396, 104253502, 124757624, 124792817, 125164428, 136340148, 136920261, 137275824, 140105717, 152258354, 160647192, 162011827, 162037796, 162202721, 163908012, 164194027, 165247593, 172649965, 174528919, 178118772, 179551797, 185990463, 198960971, 223396135, 223704418, 231943732, 247394852, 249565774, 251962950, 252109983, 252214684, 252436436
|
|||
| ChEBI ID |
CHEBI:92015
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA [cytosine-5]-methyltransferase 1 (DNMT1) | Target Info | Inhibitor | [3] |
| Poly [ADP-ribose] polymerase 1 (PARP1) | Target Info | Inhibitor | [4] | |
| KEGG Pathway | Base excision repair | |||
| NF-kappa B signaling pathway | ||||
| Cysteine and methionine metabolism | ||||
| Metabolic pathways | ||||
| MicroRNAs in cancer | ||||
| Panther Pathway | FAS signaling pathway | |||
| Pathwhiz Pathway | Methionine Metabolism | |||
| Pathway Interaction Database | Integrin-linked kinase signaling | |||
| Caspase Cascade in Apoptosis | ||||
| Notch-mediated HES/HEY network | ||||
| Regulation of retinoblastoma protein | ||||
| Reactome | Dual Incision in GG-NER | |||
| PRC2 methylates histones and DNA | ||||
| NoRC negatively regulates rRNA expression | ||||
| DNA methylation | ||||
| WikiPathways | FAS pathway and Stress induction of HSP regulation | |||
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | ||||
| Nanoparticle triggered regulated necrosis | ||||
| Corticotropin-releasing hormone | ||||
| Trans-sulfuration and one carbon metabolism | ||||
| Retinoblastoma (RB) in Cancer | ||||
| One Carbon Metabolism | ||||
| Trans-sulfuration pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | J Clin Oncol 33, 2015 (suppl, abstr TPS7097). | |||
| REF 3 | Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia. 2016 Apr;30(4):889-96. | |||
| REF 4 | Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2003 Jan 16;46(2):210-3. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.